Celltrion to establish CDMO subsidiary

The company plans to leverage its expertise in antibody development and production to gain a competitive edge

Celltrion to establish CDMO subsidiary
Dae-Kyu Ahn 1
2024-10-18 16:32:38 powerzanic@hankyung.com
Bio & Pharma

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organization (CDMO) as a wholly-owned subsidiary by the end of this year.

"The key focus of this plan is to secure a competitive edge over existing CDMO companies," the company emphasized through "Notice to Shareholders" on its homepage. "Fully leveraging Celltrion's expertise in antibody development and production with our higher productivity and lower expansion costs."

"We plan to establish a wholly-owned subsidiary of Celltrion by the end of the year, with full-scale facility expansion and commercial activities set to commence next year," the company added.

Celltrion founder and Chairman Seo Jung-jin and his eldest son, Seo Jin-seok, head of Celltrion’s business division, revealed at the "Morgan Stanley Global Healthcare Conference" in New York last month that they were considering securing production facilities and operating the business as a wholly-owned subsidiary for use in CDMO operations.

Celltrion reported that Zymfentra, its subcutaneous injection (SC) treatment for autoimmune diseases, which was launched in the US in March, has enlisted up to 80% of US pharmacy benefit managers (PBMs).

However, for patients to receive actual reimbursement based on prescriptions, all insurance companies under PBMs within the 80% range must complete the listing process, which is expected to take about two to three months.

Regarding the temporary rise in Celltrion’s cost of sales due to its merger with Celltrion Healthcare last year, the company explained that its high-cost inventory is being quickly depleted.

According to the company, it is improving its sales as planned by producing new active pharmaceutical ingredients (APIs) at lower manufacturing costs.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com

Celltrion's anti cancer drugs hold 90% market share in C.America

Celltrion's anti cancer drugs hold 90% market share in C.America

South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries.The company’s biosimilar drug Truxima, a version of Roche’s blood cancer treatment Rituxan, has held over 90% market share in Costa Ri

Celltrion establishes subsidiary in Vietnam

Celltrion establishes subsidiary in Vietnam

Celltrion Inc., South Korea’s largest biosimilar maker, said on Monday that it completed the establishment of a local subsidiary in Vietnam.Celltrion plans to obtain approval to sell its major products, including Remsima, Remsima SC, Truxima, and Herzuma this year and supply these trea

Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion to supply breast, stomach cancer treatment to Brazil

Celltrion's Herzuma Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ingredient: trastuzumab) won a bid from the Brazilian federal government, marking the fifth consecutive year of supply.As a result

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion founder and Chairman Seo Jung-jin speaks at Korea Investment Week on Sept. 11 Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract development and manufacturing organization (CDMO) market, led by Swis

Celltrion chairman announces venture into CDMO market

Celltrion chairman announces venture into CDMO market

Seo Jung-jin (center) speaks at Morgan Stanley 22nd Annual Global Healthcre Conference (Courtesy of Celltrion) South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the company said on Monday, citing its foun

(* comment hide *}